![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 35, 24930-24934, August 27, 1999
From the Departments of Surgery and Medical Physiology, Texas A&M University System Health Science Center, Temple, Texas 76504
| |
ABSTRACT |
|---|
|
|
|---|
The endothelial adherens junction is formed by
complexes of transmembrane adhesive proteins, of which The wall of exchange vessels consists of a layer of endothelial
cells that connect to each other with closely opposed intercellular junctions. A major function of the junctional connection is to maintain
the semi-permeable property of the endothelial barrier and to control
the transvascular passage of solutes, fluid, and blood cells. Four
types of junctions associated with endothelial cells have been
identified: adherens junctions
(AJ),1 tight junctions, gap
junctions, and complexus adherentes (1, 2). AJ, formed by transmembrane
adhesive proteins called cadherins, appear to be the main complex
regulating macromolecular permeability in microvascular endothelium.
Cadherins, specifically vascular endothelial (VE)-cadherin, are
associated with the actin cytoskeleton through a family of proteins
called catenins, including The endothelial permeability is affected by many agonists including
Recent evidence suggests that the AJ is involved in PMN-promoted
endothelial barrier dysfunction. Upon PMN adhesion, VE-cadherin proteolysis is accompanied by the disappearance of both VE-cadherin and
catenins from AJ (14, 16, 17). Another hyperpermeability agonist,
vascular endothelial growth factor, has been shown to increase the
transendothelial flux of albumin concomitant with a loss of VE-cadherin
(18). These studies have provided a possible linkage between PMN
activation and VE-cadherin disorganization in the regulation of
endothelial barrier function. Furthermore, evidence is accumulating
that the VE-cadherin-mediated cell-cell adhesion is controlled by a
dynamic balance between phosphorylation and dephosphorylation of the
junctional proteins including cadherins and catenins. Increased
tyrosine phosphorylation of This study focuses on the effect of activated PMNs on both endothelial
permeability and phosphorylation of AJ proteins. The results showed
that tyrosine phosphorylation of VE-cadherin and Cell Culture and Treatment--
Bovine CVECs were isolated from
postcapillary venules (about 15 µm in diameter) as described
previously (22). CVECs were routinely maintained on gelatin-coated
dishes containing 10% fetal bovine serum in complete Dulbecco's
modified Eagle's medium (with 1 mM sodium pyruvate, 2 mM L-glutamine, 15 mM HEPES, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin B, and 25 units/ml heparin). The cells exhibited properties characteristic of the endothelial cell, such as typical cobblestone morphology, positive immunofluorescent staining for factor VIII antigen, uptake of
diacetylated low density lipoprotein, and the ability to form tubes
(22). Cells were used at passages 6-14 and grown to confluence before
treatment with drugs: complement 5a (C5a) 10 Isolation of Porcine PMNs--
Platelet-poor plasma was obtained
by centrifuging 40 ml of plasma at 2500 × g for 10 min. The plasma was added to Hanks' buffer solution to a concentration
of 10% and used as diluent or washing solution for the following
procedures. To isolate PMNs, 20 ml of whole blood were diluted with 40 ml of Hanks' buffer solution, carefully layered on top of a 59%
isotonic Percoll column, and centrifuged at 400 × g
for 20 min. The top band on the centrifuged Percoll column (containing
lymphocytes) was discarded. The pellet containing red blood cells and
PMNs was collected and mixed with two parts (v/v) of 2.5% gelatin in
Hanks' buffer solution for incubation at 37 °C for 45 min. The
supernatant was collected and centrifuged at 300 × g
for 10 min. The remaining red cell pellet was then removed by hypotonic
hemolysis. PMNs were harvested and washed twice by centrifuging at
400 × g for 5 min. From this technique, 20 ml of blood
yielded 106-107 cells, of which 90-95% were
PMNs. In vitro analyses demonstrated that the isolated PMNs
were viable and displayed normal chemotaxis function and metabolic
oxygenation activity (10).
Immunoprecipitation and Western Analysis--
CVECs were treated
as described above for 30 min at 37 °C, washed with
phosphate-buffered saline, and lysed on ice for 30 min with 300 µl of
radioimmune precipitation buffer (1× phosphate-buffered saline, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) containing the
protease inhibitors phenylmethylsulfonyl fluoride (0.1 mg/ml), aprotinin (1 µg/ml), and sodium orthovanadate (1 mM)
(Sigma). After centrifugation for 3 min at 14,000 rpm, cell lysates
were removed, and protein concentrations were determined using the Bradford assay. For immunoprecipitation (IP), 100 µg of cell lysate was used in 1 ml of radioimmune precipitation buffer. Five µg of
antibody against phosphotyrosine PY20 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, California) was added, and the samples were rotated for
1 h at room temperature. After this, 20 µl of protein A/G
PLUS-agarose (Santa Cruz) was added, and the IP was continued overnight
at 4 °C. After washing five times with radioimmune precipitation buffer, the samples were electrophoresed on 6% SDS-polyacrylamide electrophoresis gels and blotted to nitrocellulose membrane. Primary antibodies to Measurement of Endothelial Permeability--
CVECs were seeded
at a density of 105 cells/cm2 on gelatin-coated
Costar Transwell membranes (VWR, Houston, Texas) and allowed to grow
4-5 days until confluent. Cells were washed with phosphate-buffered saline and treated with drugs or PMNs for 30 min at 37 °C.
Fluorescein isothiocyanate-labeled bovine serum albumin (Sigma) was
then added to the top (luminal) chamber at a concentration of 3.5 mg/ml, and the plates were returned to incubation at 37 °C. After 45 min, samples were removed from the bottom (abluminal) and luminal chambers and analyzed by fluorometry. Sample readings were converted with the use of a standard curve to albumin concentration. These concentrations were then used in the following equation to determine the permeability coefficient of albumin (Pa),
Pa = [A]/t × 1/A × V/[L], where [A] = abluminal concentration,
t = time in s, A = area of membrane in
cm2, V = volume of abluminal chamber, and
[L] = luminal concentration.
Immunocytochemistry--
CVECs were grown to confluence on
gelatin-coated coverslips and treated with C5a-activated PMNs for 30 min at 37 °C. They were fixed with 2% paraformaldehyde for 15 min
and permeabilized with 100% acetone for 2 min for Data Analysis--
In the immunoblot studies, representative
images of Western blots were selected to present. To compare the
difference in optical densities of protein bands, the optical density
values obtained from treated samples were expressed as a percentage of
the controls. Analysis of variance was used to evaluate the
significance of intergroup differences in the immunoblot analyses and
permeability studies. A value of p < 0.05 was
considered significant for the comparisons.
Increases in Tyrosine and Serine Phosphorylation Induce
Hyperpermeability in CVEC Monolayers--
To study the causes and
effects of transendothelial flux of macromolecules with respect to
microvascular permeability, it was necessary to adapt a model
previously used with large vascular endothelial cells for use with our
venular endothelial cells. Our preliminary studies revealed that
coating the polycarbonate membranes with gelatin was superior to
fibronectin, and the gelatin imposed no major restriction to albumin
clearance. Membranes with a gelatin coating and no cells had a 14-fold
higher Pa than membranes with gelatin and a
confluent CVEC monolayer. The model was tested with drugs that would
increase tyrosine and serine phosphorylation, two events that are known
to be involved in the regulation of endothelial permeability in intact
venules (9, 23). Fig. 1 shows that PAO (a
tyrosine phosphatase inhibitor), phorbol 12-myristate 13-acetate (a
serine kinase activator), and calyculin A (a serine phosphatase
inhibitor) increase albumin permeability across the monolayer by 35, 75, and 74%, respectively. Hyperpermeability was also observed with
CVEC monolayers when the typical inflammatory agonists C5a-activated PMNs Induce Protein Flux Across Microvascular
Endothelial Monolayers--
Fig. 2 shows
that activated PMNs increase albumin permeability across CVEC
monolayers to ~145% that of control cells. It is also clear from the
data that nonactivated PMNs and C5a alone do not affect monolayer
permeability (Fig. 2). We decided then to determine if activated PMNs
increase permeability through processes involving phosphorylation. As
Fig. 2 shows, we were able to attenuate the increases in permeability
provoked by activated PMNs with both DAM and genistein, tyrosine kinase
inhibitors, and BIM and Go6976, serine kinase inhibitors. Additionally,
BIM seemed to cause a decrease in the basal permeability, but the
significance of this effect has not been determined.
Activated PMNs Induce Tyrosine Phosphorylation of Endothelial
Junctional Proteins--
Knowing that PMNs are involved in
hyperpermeability processes involving tyrosine and serine
phosphorylation events, we looked for changes in phosphorylation levels
of proteins found at intercellular junctions and, therefore, suspected
of regulating endothelial integrity. Fig.
3 shows that activated PMNs increase
tyrosine phosphorylation of Distribution of PMN-induced vascular leakage has long been implicated in the
development of coronary microvascular dysfunction during
ischemia-reperfusion injury and other types of cardiovascular disorders
(12, 13, 24-27). Our study is the first systematic examination of the
direct effects of PMN activation on the function and structure of
coronary microvascular endothelial cells. We had previously
demonstrated the interaction of PMNs with the endothelium using intact,
perfused coronary venules and arterioles (10). We modified existing
monolayer models (12, 13, 18) to accommodate CVECs to study processes occurring at the molecular level in these cells. Compared with the
intact, perfused coronary venules, the CVEC monolayer exhibited a
higher basal permeability but a similar responsiveness to the hyperpermeability stimulators.
The complexity of the precise molecular events that lead to
microvascular leakage is becoming evident. To allow large molecules and even blood cells to pass through the endothelial layer, individual endothelial cells must contract to form gaps. In this process, the
intercellular junction may undergo conformational changes, facilitating
the gap formation and macromolecular transflux. VE-cadherin, a
transmembrane protein, and The precise mechanism by which PMNs increase microvascular permeability
has not been established. A body of evidence supports that the leakage
is mainly attributed to PMN-derived cytotoxic mediators including
oxygen radicals and various proteases (28-31). At the site of PMN
adhesion, large amounts of the cytotoxic factors are released and
accumulate, initiating a full cascade of signaling reactions in the
endothelium. Ultimately, endothelial cell contraction occurs, and
intercellular gaps are formed. Based on our previous and present
studies, it appears that protein phosphorylation is one of the
signaling events that is activated in response to PMN adhesion, and
these kinase cascades result in the hyperpermeability response. In
support of this, we found that activated PMNs induce increases in
tyrosine phosphorylation of AJ proteins accompanied by an increase in
permeability. Interestingly, we also discovered that serine kinase
inhibitors could attenuate the permeability increase provoked by PMNs,
and a serine phosphatase inhibitor increased basal permeability.
However, our attempts to detect serine phosphorylation of This study is the first to correlate PMN activation with
phosphorylation of AJ proteins and hyperpermeability in cultured microvascular endothelial monolayers. We had previously reported that
tyrosine phosphorylation of the focal adhesion proteins paxillin and
focal adhesion kinase occurs in CVEC monolayers in conjunction with a
breakdown of endothelial barrier function (23). Therefore, we now have
evidence that alterations in both the focal adhesion complex and the AJ
can result in hyperpermeability of the microvascular endothelium and
that activated PMNs can induce at least some of these events. We have
established the appropriate model for further studies aimed at
methodically dissecting the molecular events associated with changes in
CVEC permeability.
-catenin is
known to connect the junctional protein vascular endothelial
(VE)-cadherin to the cytoskeleton and to play a signaling role in the
regulation of junction-cytoskeleton interaction. In this study, we
investigated the effect of neutrophil activation on endothelial
monolayer integrity and on
-catenin and VE-cadherin modification.
Treatment of cultured bovine coronary endothelial monolayers with
C5a-activated neutrophils resulted in an increase in permeability as
measured by albumin clearance across the monolayer. Furthermore, large
scale intercellular gap formation was observed in coincidence with the
hyperpermeability response. Immunofluorescence analysis showed that
-catenin and VE-cadherin staining changed from a uniform
distribution along the membrane of control cells to a diffuse pattern
for both proteins and finger-like projections for
-catenin in
neutrophil-exposed monolayers. Correlatively, there was an increase in
actin stress fiber formation in treated cells. Finally,
-catenin and
VE-cadherin from neutrophil-treated endothelial cells showed a
significant increase in tyrosine phosphorylation. Our results are the
first to link neutrophil-mediated changes in adherens junctions with intercellular gap formation and hyperpermeability in microvascular endothelial cells. These data suggest that neutrophils may
regulate endothelial barrier function through a process conferring
conformational changes to
-catenin and VE-cadherin.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-catenin,
-catenin, and plakoglobin
(3, 4).
-thrombin, histamine, and phorbol esters (5-9) as well as by a
group of inflammatory cells, namely polymorphonuclear leukocytes (PMNs)
(10-14). At the site of injury or inflammation, circulating PMNs often
adhere to and subsequently migrate through the endothelium and enter
surrounding tissues (15). It has long been documented that the process
of PMN adherence and migration is associated with an increase in
endothelial permeability (10, 11). Although much work has been
dedicated to identify PMN-derived hyperpermeability factors (11-14),
little is known about the molecular targets of activated PMNs and the
derived factors. Within this context, whether PMNs affect microvascular
barrier function by altering the structural and functional integrity of
the endothelium remains elusive.
-catenin resulted in a dissociation of
the catenin from cadherin and from the cytoskeleton, leading to a weak
AJ (19, 20). Similarly, tyrosine phosphorylation of VE-cadherin and
-catenin occurred in loose AJ and was notably reduced in tightly
confluent monolayers (21).
-catenin was
increased when cultured coronary venular endothelial cells (CVECs) were
exposed to activated PMNs.
-Catenin and VE-cadherin staining
revealed a marked decrease in the amount of these proteins at the cell
periphery upon stimulation by PMNs. Correspondingly, PMN-treated
monolayers showed a significant increase in permeability as measured by
albumin clearance. This work is the first to correlate hyperpermeability and tyrosine phosphorylation of junctional proteins in response to PMNs in microvascular endothelial cells.
![]()
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
7
M and phenylarsine oxide (PAO) 10
5
M (Sigma); 10
5 M damnacanthal
(DAM), 10
6 M bisindolylmaleimide I (BIM),
10
5 M phorbol 12-myristate 13-acetate,
10
8 M genistein, 10
7
M Go6976, and 10
8 M calyculin A
(Calbiochem). PMNs were isolated from porcine blood as described below,
activated with C5a for 15 min, then added to the CVECs at a
concentration of 106/ml.
-catenin and VE-cadherin (Santa Cruz) were used at 0.5 µg/ml for 1 h followed by secondary antibodies conjugated to
horseradish peroxidase (Santa Cruz). Protein bands were detected using
LumiGLO chemiluminescent substrate (New England BioLabs, Beverly, MA).
Images of the bands were scanned by reflectance-scanning densitometry,
and the intensity of the bands was quantified using NIH image software.
For non-IP Western blotting, 20 µg of protein was run/lane.
-catenin staining
only. Primary antibodies to
-catenin and VE-cadherin were applied
for 1.5 h followed by secondary antibodies conjugated to
fluorescein isothiocyanate (Santa Cruz) for 45 min. Actin was
visualized using rhodamine phalloidin (Molecular Probes, Eugene, OR)
following permeabilization. Coverslips were then mounted on slides, and
cells were examined under a Zeiss Axiovert 135 inverted microscope
equipped with fluorescence filter sets and photographed using Kodak
GoldMax 400 film.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-thrombin and
histamine were applied (data not shown). We therefore established a
monolayer model using a two-chambered system that would allow us to
detect increases in permeability.

View larger version (54K):
[in a new window]
Fig. 1.
Albumin permeability of CVEC monolayers in
response to PAO, phorbol 12-myristate 13-acetate, and calyculin A. CVECs were grown to confluence on Transwell membranes and treated with
PAO (10
5 M), phorbol 12-myristate 13-acetate
(PMA) (10
5 M), or calyculin A
(10
8 M) for 30 min. Fluorescein
isothiocyanate-albumin was then added to the luminal chamber, and
permeability (Pa) was calculated after 45 min.
(Pa) values were expressed as percentage of control
cells. *, p < 0.05.

View larger version (47K):
[in a new window]
Fig. 2.
PMNs induced hyperpermeability in CVECs.
CVECs were grown to confluence on Transwell membranes and treated for
30 min with control (a), C5a (b), PMNs
(c), PMNs/C5a (d), DAM (e),
PMNs/C5a/DAM (f), BIM (g), PMNs/C5a/BIM
(h), genistein (i), PMNs/C5a/Genistein (j),
Go6976 (k), and PMNs/C5a/Go6976 (l). Albumin
clearance across the membrane was measured followed by calculation of
the permeability coefficient. Data are shown as the percentage of
control. *, p < 0.05.
-catenin ~225% above control levels.
As expected, this increase could be attenuated by the addition of a
tyrosine kinase inhibitor (DAM); however, we also somewhat unexpectedly observed an attenuation of this increase with the addition of a serine
kinase inhibitor (BIM) (Fig. 3). Another AJ protein, VE-cadherin,
showed an ~100% increase in tyrosine phosphorylation content after
exposing CVECs to activated PMNs (Fig.
4). As with
-catenin, the increase in
tyrosine phosphorylation of VE-cadherin brought on by activated PMNs
was attenuated with DAM and BIM (Fig. 4). These results suggest an
interaction between tyrosine and serine phosphorylation events as they
relate to AJ proteins and monolayer permeability. Additionally,
C5a-activated PMNs appear to be a more potent stimulator of AJ protein
tyrosine phosphorylation than the potent tyrosine phosphatase inhibitor
PAO (Figs. 3 and 4).

View larger version (51K):
[in a new window]
Fig. 3.
PMN induced tyrosine phosphorylation of
-catenin. CVECs were treated with PMNs and
drugs for 30 min. In A, protein levels reflect total cell
lysate, and phosphorylation levels were obtained after IP with a
phosphotyrosine antibody. Both Westerns were probed with a
-catenin
antibody. In B, the phosphorylation levels were quantitated
by scanning densitometry and comparing phosphorylation levels to total
-catenin levels. For both A and B, results are
shown with control (a), C5a (b), PMNs
(c), PMNs/C5a (d), DAM (e),
PMNs/C5a/DAM (f), BIM (g), PMNs/C5a/BIM
(h), and PAO (i). *, p < 0.05. O.D., optical density.

View larger version (52K):
[in a new window]
Fig. 4.
PMN induced tyrosine phosphorylation of
VE-cadherin. CVECs were treated with PMNs and drugs for 30 min. In
A, protein levels reflect total cell lysate, and
phosphorylation levels were obtained after IP with a phosphotyrosine
antibody. Both Westerns were probed with a VE-cadherin antibody. In
B, the phosphorylation levels were quantitated by scanning
densitometry and comparing phosphorylation levels to total VE-cadherin
levels. For both A and B, results are shown with
control (a), C5a (b), PMNs (c),
PMNs/C5a (d), DAM (e), PMNs/C5a/DAM
(f), BIM (g), PMNs/C5a/BIM (h), and
PAO (i). *, p < 0.05. O.D.,
optical density.
-Catenin, VE-cadherin, and Actin in Response to
Activated PMNs--
In view of the result that activated PMNs induced
phosphorylation either directly or indirectly of two major AJ proteins, we wanted to determine if changes in cellular distribution accompanied this hyperphosphorylation. Confluent CVEC monolayers were exposed to
activated PMNs and then subjected to immunocytochemistry to detect
changes in
-catenin and/or VE-cadherin localization. In addition,
because VE-cadherin is associated with the actin cytoskeleton through
the catenins, we examined actin distribution in PMN-treated cells. In
control cells,
-catenin is uniformly dispersed around the periphery
of a tightly confluent monolayer (Fig.
5A). When the cells are
treated with activated PMNs, we see widespread gap formation as the
cells retract and a loss of
-catenin staining in areas where
individual cells have lost contact with neighboring cells (Fig.
5B). Note also that
-catenin assumes a finger-like configuration between these minimal cell contacts (Fig. 5B).
VE-cadherin shows a peripheral staining pattern in control CVEC
monolayers (Fig. 5C). However, PMN-treated cells show
widespread gap formation and a diffuse staining pattern for
VE-cadherin, leaving little if any VE-cadherin at the cell periphery
(Fig. 5D). We surmised that for cells to retract in response
to PMNs, there are probably accompanying changes in the actin
cytoskeleton. Actin staining of control cells revealed that most of the
F-actin was located at the cell periphery (Fig. 5E).
However, in PMN-treated cells, we consistently observed an increase in
stress fiber formation (Fig. 5F), which indicates cell
contraction and shape change. In all of the PMN-treated endothelial
monolayers, adherent PMNs were often observed where intercellular gaps
were seen (Fig. 5B, arrow).

View larger version (117K):
[in a new window]
Fig. 5.
Immunofluorescent staining of
-catenin, actin, and VE-cadherin in CVECs.
Cells were grown to confluence and treated with C5a-activated PMNs for
30 min. Panels A, C, and E represent
control staining for
-catenin, VE-cadherin, and actin, respectively.
Panels B, D, and F represent
-catenin, VE-cadherin, and actin staining after PMN treatment. In
panels B and D, note the gap formation and
absence of
-catenin and VE-cadherin in areas where the cells have
separated. The arrow in panel B points to a PMN
adhered to the monolayer. In panel F, note the increase in
stress fiber formation in the cells compared with control actin
staining in panel E.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
-catenin, a signaling protein that links
cadherins to the actin cytoskeleton, were found to exhibit increases in
tyrosine phosphorylation levels concomitant with an increase in
permeability. We suggest that this phosphorylation is an important
signal responsible for breaking down the AJ and diminishing the ability
of neighboring cells to interact. Our results and those of others
showed the disappearance of AJ proteins at the cell periphery under
conditions of hyperpermeability (14, 16, 17). Additionally, we observed
an increase in the formation of actin stress fibers that coincides with
the AJ breakdown and permeability increases. In PMN-treated monolayers,
although not all cells show stress fiber formation, there is an overall
increase in stress fiber formation across the monolayer
versus control cell monolayers. Presumably these stress
fibers make contact with opposite sides of the cell membrane and
"pull" the cell into a spherical shape, breaking the contacts
between neighboring cells. The question then becomes, to what protein
or protein complex are the actin fibers anchoring during
hyperpermeability situations? Our hypothesis is that AJ proteins anchor
the peripheral actin filaments under resting conditions and allow for
the integrity of the monolayer to remain intact. In response to
agonists, actin stress fibers form and interact with structure(s)
including the AJ to instigate changes in cellular morphology, leading
to a weak or diminished AJ. Phosphorylation of VE-cadherin and
-catenin may be a critical signaling event that elicits such
structural changes. In further support of this, our data show that
inhibiting phosphorylation of VE-cadherin and
-catenin blocks the
hyperpermeability response in the endothelial cells.
-catenin
and VE-cadherin were unsuccessful. It is likely that activated PMNs
initiate events that directly or indirectly up-regulate both the
tyrosine and serine phosphorylation pathways, which may interact
(cross-talk) with each other. Our opinion is that both types of
phosphorylation are necessary to instigate hyperpermeability of CVEC monolayers.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants HL-52221 and HL-61507 (NHLBI).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
A recipient of National Institutes of Health Research Career Award
K02 HL-03606. To whom correspondence should be addressed: Depts. of
Surgery and Medical Physiology, Texas A&M University System Health
Science Center, 1901 South 1st St., Bldg. 4, Temple, TX
76504. Tel.: 254-899-2270; Fax: 254-899-2371; E-mail:
yuan@tamu.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: AJ, adherens junction; VE, vascular endothelial; PMN, polymorphonuclear leukocyte; PAO, phenylarsine oxide; CVEC, coronary venular endothelial cell; C5a, complement 5a; DAM, damnacanthal; BIM, bisindolylmaleimide I; IP, immunoprecipitation; Pa, permeability coefficient of albumin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Rubin, L. L. (1992) Cell Biol. 4, 830-833 |
| 2. | Dejana, E., Corada, M., and Lampugnani, M. G. (1995) FASEB J. 9, 910-918[Abstract] |
| 3. | Kemler, R. (1993) Trends Genet. 9, 317-321[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Lampugnani, M. G.,
Corada, M.,
Caveda, L.,
Breviario, F.,
Ayalon, O.,
Geiger, B.,
and Dejana, E.
(1995)
J. Cell Biol.
129,
203-217 |
| 5. | Ehringer, W. D., Edwards, M. J., and Miller, F. N. (1996) J. Cell. Physiol. 167, 562-569[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Drake, W. T., Lopes, N. N., Fenton, J. W., II, and Issekutz, A. C. (1992) Lab. Invest 67, 617-627[Medline] [Order article via Infotrieve] |
| 7. |
Schaeffer, R. C.,
Gong, F.,
Bitrick, M. S.,
and Smith, T. L.
(1993)
Am. J. Physiol.
264,
H1798-H1809 |
| 8. |
Yuan, Y.,
Granger, H. J.,
Zawieja, D. C.,
DeFily, D. V.,
and Chilian, W. M.
(1993)
Am. J. Physiol.
264,
H1734-H1739 |
| 9. |
Huang, Q.,
and Yuan, Y.
(1997)
Am. J. Physiol.
273,
H2442-H2451 |
| 10. |
Yuan, Y.,
Mier, R. A.,
Chilian, W. M.,
Zawieja, D. C.,
and Granger, H. J.
(1995)
Am. J. Physiol.
268,
H490-H498 |
| 11. | Beynon, H. L. C., Davies, K. A., Haskard, D. O., and Walport, M. J. (1994) J. Immunol 153, 3160-3167[Abstract] |
| 12. | Gibbs, L. S., Lai, L., and Malik, A. B. (1990) J. Cell. Physiol. 145, 496-500[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Rosengren, S.,
Olofsson, A. M.,
von Andrian, U. H.,
Lundgren-Akerlund, E.,
and Arfors, K. E.
(1991)
J. Appl. Physiol
71,
1322-1330 |
| 14. |
Carden, D.,
Xiao, F.,
Moak, C.,
Willis, B. H.,
Robinson-Jackson, S.,
and Alexander, S.
(1998)
Am. J. Physiol.
275,
H385-H392 |
| 15. | Burns, A. R., Walker, D. C., Brown, E. S., Thurmon, L. T., Bowden, R. A., Keese, C. R., Simon, S. I., Entman, M. L., and Smith, C. W. (1997) J. Immunol. 159, 2893-2903[Abstract] |
| 16. |
Del Maschio, A.,
Zanetti, A.,
Corada, M.,
Rival, Y.,
Ruco, L.,
Lampugnani, M. G.,
and Dejana, E.
(1996)
J. Cell Biol.
135,
497-510 |
| 17. |
Allport, J. R.,
Ding, H.,
Collins, T.,
Gerritsen, M. E.,
and Luscinskas, F. W.
(1997)
J. Exp. Med.
186,
517-527 |
| 18. |
Kevil, C. G.,
Payne, D. K.,
Mires, E.,
and Alexander, J. S.
(1998)
J. Biol. Chem.
273,
15099-15103 |
| 19. |
Kypta, R. M.,
Su, H.,
and Reichardt, L. F.
(1996)
J. Cell Biol.
134,
1519-1529 |
| 20. |
Matsuyoshi, N.,
Hamaguchi, M.,
Taniguchi, S.,
Nagfuchi, A.,
Tsukita, S.,
and Takeichi, M.
(1992)
J. Cell Biol.
118,
703-714 |
| 21. | Lampugnani, M. G., Corada, M., Andriopoulou, P., Esser, S., Risau, W., and Dejana, E. (1997) J. Cell Sci. 110, 2065-2077[Abstract] |
| 22. |
Schelling, M. E.,
Meininger, C. J.,
Hawker, J. R., Jr.,
and Granger, H. J.
(1988)
Am. J. Physiol.
254,
H1211-H1217 |
| 23. |
Yuan, Y.,
Meng, F. Y.,
Huang, Q.,
Hawker, J.,
and Wu, H. M.
(1998)
Am. J. Physiol
275,
H84-H93 |
| 24. |
Huang, A. J.,
Manning, J. E.,
Bandak, T. M.,
Ratau, M. C.,
Hanser, K. R.,
and Silverstein, S. C.
(1993)
J. Cell Biol.
120,
1371-1380 |
| 25. | Beesley, J. E., Pearson, J. D., Carleton, J. S., Hutchings, A., and Gordon, J. L. (1978) J. Cell Sci. 33, 85-101[Abstract] |
| 26. |
Furie, M. B.,
Naprstek, B. L.,
and Silverstein, S. C.
(1987)
J. Cell Sci.
88,
161-175 |
| 27. | Taylor, R. F., Price, T. H., Schwartz, S. M., and Dale, D. C. (1981) J. Clin. Invest. 67, 584-587 |
| 28. | Sepper, R., Konttinen, Y. T., Ingman, T., and Sorsa, T. (1995) J. Clin. Immunol 15, 27-34[CrossRef][Medline] [Order article via Infotrieve] |
| 29. | Smedley, L. A., Tonnesen, M. G., Sandhaus, R. A., Haslett, C., Guthrie, L. A., Johnston, R. B., Henson, P. M., and Worthen, G. S. (1986) J. Clin. Invest. 77, 1233-1243 |
| 30. | Suttorp, N., Nolte, A., Wilke, A., and Drenchkhahn, D. (1993) Int. J. Microcirc. Clin. Exp. 13, 187-203[Medline] [Order article via Infotrieve] |
| 31. | Weiss, S. J., and Regiani, S. (1984) J. Clin. Invest 73, 1297-1303 |
This article has been cited by other articles:
![]() |
N. Gaudreault, R. M. Perrin, M. Guo, C. P. Clanton, M. H. Wu, and S. Y. Yuan Counter Regulatory Effects of PKC{beta}II and PKC{delta} on Coronary Endothelial Permeability Arterioscler. Thromb. Vasc. Biol., August 1, 2008; 28(8): 1527 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guo, J. W. Breslin, M. H. Wu, C. J. Gottardi, and S. Y. Yuan VE-cadherin and {beta}-catenin binding dynamics during histamine-induced endothelial hyperpermeability Am J Physiol Cell Physiol, April 1, 2008; 294(4): C977 - C984. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Adamson, J. C. Ly, R. K. Sarai, J. F. Lenz, A. Altangerel, D. Drenckhahn, and F. E. Curry Epac/Rap1 pathway regulates microvascular hyperpermeability induced by PAF in rat mesentery Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1188 - H1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Vestweber VE-Cadherin: The Major Endothelial Adhesion Molecule Controlling Cellular Junctions and Blood Vessel Formation Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 223 - 232. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Puana, R. K. McAllister, F. A. Hunter, J. Warden, and E. W. Childs Morphine Attenuates Microvascular Hyperpermeability via a Protein Kinase A-Dependent Pathway Anesth. Analg., February 1, 2008; 106(2): 480 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Allingham, J. D. van Buul, and K. Burridge ICAM-1-Mediated, Src- and Pyk2-Dependent Vascular Endothelial Cadherin Tyrosine Phosphorylation Is Required for Leukocyte Transendothelial Migration J. Immunol., September 15, 2007; 179(6): 4053 - 4064. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jain, G. Venkatraman, and S. K. Batra Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation Clin. Cancer Res., March 1, 2007; 13(5): 1374 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Orrington-Myers, X. Gao, P. Kouklis, M. Broman, A. Rahman, S. M. Vogel, and A. B. Malik Regulation of lung neutrophil recruitment by VE-cadherin Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L764 - L771. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Yuan New insights into eNOS signaling in microvascular permeability Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1029 - H1031. [Full Text] [PDF] |
||||
![]() |
Y.-J. Na, S.-H. Yang, D.-W. Baek, D.-H. Lee, K.-H. Kim, Y.-M. Choi, S.-T. Oh, Y.-S. Hong, J.-Y. Kwak, and K.-S. Lee Effects of peritoneal fluid from endometriosis patients on the release of vascular endothelial growth factor by neutrophils and monocytes Hum. Reprod., July 1, 2006; 21(7): 1846 - 1855. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Breslin, H. Sun, W. Xu, C. Rodarte, A. B. Moy, M. H. Wu, and S. Y. Yuan Involvement of ROCK-mediated endothelial tension development in neutrophil-stimulated microvascular leakage Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H741 - H750. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Mehta and A. B. Malik Signaling Mechanisms Regulating Endothelial Permeability Physiol Rev, January 1, 2006; 86(1): 279 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Tinsley, J. W. Breslin, N. R. Teasdale, and S. Y. Yuan PKC-dependent, burn-induced adherens junction reorganization and barrier dysfunction in pulmonary microvascular endothelial cells Am J Physiol Lung Cell Mol Physiol, August 1, 2005; 289(2): L217 - L223. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.L.S. Roussoulieres, O. Raisky, L. Chalabreysse, G. Dureau, C. Cerutti, C. Thieblemont, P. Boissonnat, L. Sebbag, J.-F. Obadia, J. Ninet, et al. Identification and Characterization of Two Genes (MIP-1{beta}, VE-CADHERIN) Implicated in Acute Rejection in Human Heart Transplantation: Use of Murine Models in Tandem With cDNA Arrays Circulation, May 24, 2005; 111(20): 2636 - 2644. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Cook-Mills and T. L. Deem Active participation of endothelial cells in inflammation J. Leukoc. Biol., April 1, 2005; 77(4): 487 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Lambeng, Y. Wallez, C. Rampon, F. Cand, G. Christe, D. Gulino-Debrac, I. Vilgrain, and P. Huber Vascular Endothelial-Cadherin Tyrosine Phosphorylation in Angiogenic and Quiescent Adult Tissues Circ. Res., February 18, 2005; 96(3): 384 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Tinsley, N. R. Teasdale, and S. Y. Yuan Myosin light chain phosphorylation and pulmonary endothelial cell hyperpermeability in burns Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L841 - L847. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Breslin and S. Y. Yuan Involvement of RhoA and Rho kinase in neutrophil-stimulated endothelial hyperpermeability Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1057 - H1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kurizaki, M. Abe, S. D. Sanderson, C. A. Enke, and J. Baranowska-Kortylewicz Role of polymorphonuclear leukocytes, nitric oxide synthase, and cyclooxygenase in vascular permeability changes induced by C5a agonist peptides Mol. Cancer Ther., January 1, 2004; 3(1): 85 - 91. [Abstract] [Full Text] |
||||
![]() |
M. Guo, M. H. Wu, H. J. Granger, and S. Y. Yuan Transference of recombinant VE-cadherin cytoplasmic domain alters endothelial junctional integrity and porcine microvascular permeability J. Physiol., January 1, 2004; 554(1): 78 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Tinsley, N. R. Teasdale, and S. Y. Yuan Involvement of PKC{delta} and PKD in pulmonary microvascular endothelial cell hyperpermeability Am J Physiol Cell Physiol, January 1, 2004; 286(1): C105 - C111. [Abstract] [Full Text] [PDF] |
||||
![]() |